These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39178210)

  • 21. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
    Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
    ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
    Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
    Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metal-Phenolic Network-Encapsulated Nanovaccine with pH and Reduction Dual Responsiveness for Enhanced Cancer Immunotherapy.
    Zhou X; Su Q; Zhao H; Cao X; Yang Y; Xue W
    Mol Pharm; 2020 Dec; 17(12):4603-4615. PubMed ID: 33175556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
    Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
    ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses.
    Sheng S; Zhang H; Li X; Chen J; Wang P; Liang Y; Li C; Li H; Pan N; Bao X; Liu M; Zhao L; Li X; Guan P; Wang X
    J Nanobiotechnology; 2024 May; 22(1):267. PubMed ID: 38764014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
    Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
    Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
    Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
    J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
    Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
    Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
    Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
    Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large-Pore Mesoporous-Silica-Coated Upconversion Nanoparticles as Multifunctional Immunoadjuvants with Ultrahigh Photosensitizer and Antigen Loading Efficiency for Improved Cancer Photodynamic Immunotherapy.
    Ding B; Shao S; Yu C; Teng B; Wang M; Cheng Z; Wong KL; Ma P; Lin J
    Adv Mater; 2018 Dec; 30(52):e1802479. PubMed ID: 30387197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions.
    Mody KT; Mahony D; Cavallaro AS; Stahr F; Qiao SZ; Mahony TJ; Mitter N
    Int J Pharm; 2014 Apr; 465(1-2):325-32. PubMed ID: 24583208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold.
    Nguyen TL; Cha BG; Choi Y; Im J; Kim J
    Biomaterials; 2020 May; 239():119859. PubMed ID: 32070828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
    Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
    Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
    Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
    ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
    Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
    Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
    Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
    Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.